IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Researchers may have made a significant advancement in forecasting one of the most perilous aspects of cancer — metastasis. In this video, we delve into an innovative AI model crafted by scholars at ...

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Why some cancers spread while others remain confined to their original location remains one of the most perplexing questions ...

Scientists may have just taken a huge step toward predicting one of cancer’s most dangerous behaviors — metastasis. In this video, we explore a groundbreaking artificial intelligence model developed ...

Scientists have developed an AI system that analyzes complex gene-expression signatures to estimate the likelihood that a tumor will spread.

John Avlon talks with Annabelle Gurwitch about surviving stage-4 lung cancer—and what her experience reveals about America’s broken health system.

Gut microbiota may shape liver metastasis in small cell lung cancer and influence treatment response. Read more.

Assessment of Functional Status of Human Leukocyte Antigen Class I Genes in Cancer Tissues in the Context of Personalized Neoantigen Peptide Vaccine Immunotherapy Lymph node metastasis (LNM) ...

Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in ...

Novo Nordisk (NVO) stock is in focus as FDA declines a cancer drug approval for Incyte (INCY) and MacroGenics (MGNX) due to ...